MX2013007411A - Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3). - Google Patents

Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).

Info

Publication number
MX2013007411A
MX2013007411A MX2013007411A MX2013007411A MX2013007411A MX 2013007411 A MX2013007411 A MX 2013007411A MX 2013007411 A MX2013007411 A MX 2013007411A MX 2013007411 A MX2013007411 A MX 2013007411A MX 2013007411 A MX2013007411 A MX 2013007411A
Authority
MX
Mexico
Prior art keywords
lower alkyl
substituted
halogen
phenyl
pyridazinyl
Prior art date
Application number
MX2013007411A
Other languages
English (en)
Other versions
MX340508B (es
Inventor
Hasane Ratni
Henner Knust
Matthias Nettekoven
Walter Vifian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013007411A publication Critical patent/MX2013007411A/es
Publication of MX340508B publication Critical patent/MX340508B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (I) en donde R1 es (A) o es fenilo, piridinilo o piridazinilo, en donde fenilo, piridinilo y piridazinilo pueden ser sustituidos opcionalmente por ciano, alquilo inferior, fenilo sustituido con halógeno, [1,2,4]oxadiazol-3-ilo sustituido por alquilo inferior o por 2-oxo-piperidin-1-ilo; X es NR u O; R es -C(O)-alquilo inferior, -C(O)-cicloalquilo substituido por alquilo inferior, cicloalquilo o es fenilo, piridinilo o piridazinilo, en donde fenilo, piridinilo y piridazinilo pueden estar sustituidos opcionalmente por alquilo inferior, alcoxi inferior, ciano, -C(O)-alquilo inferior, halógeno o alquilo inferior substituido por halógeno; R2 es hidrógeno o alquilo inferior; R3 es hidrógeno, halógeno, ciano, alquilo inferior o alquilo inferior sustituido por halógeno; R4 es hidrógeno o alquilo inferior; en donde R2 y no son simultáneamente hidrógeno o alquilo inferior; R5 es alquilo inferior; R6 es halógeno, hidroxi, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, S(O)2-alquilo inferior o ciano; o a una sal de adición ácida farmacéuticamente activas de los mismos. Se ha encontrado que los presentes compuestos son antagonistas del receptor NK-3 de potencial elevado para el tratamiento de la depresión, el dolor, la psicosis, la enfermedad de Parkinson, la esquizofrenia, la ansiedad y el trastorno de hiperactividad con déficit de atención (ADHD).
MX2013007411A 2011-01-07 2012-01-03 Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3). MX340508B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150352 2011-01-07
PCT/EP2012/050034 WO2012093109A1 (en) 2011-01-07 2012-01-03 Pyrrolidine derivatives as nk3 antagonists

Publications (2)

Publication Number Publication Date
MX2013007411A true MX2013007411A (es) 2013-07-29
MX340508B MX340508B (es) 2016-07-11

Family

ID=45443125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007411A MX340508B (es) 2011-01-07 2012-01-03 Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).

Country Status (12)

Country Link
US (1) US8618303B2 (es)
EP (1) EP2661432B1 (es)
JP (1) JP5763211B2 (es)
KR (1) KR101522125B1 (es)
CN (1) CN103282357B (es)
BR (1) BR112013017059A2 (es)
CA (1) CA2821640A1 (es)
ES (1) ES2526420T3 (es)
HK (1) HK1187914A1 (es)
MX (1) MX340508B (es)
RU (1) RU2598604C2 (es)
WO (1) WO2012093109A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US20110152233A1 (en) * 2009-12-18 2011-06-23 Henner Knust Pyrrolidine compounds
NZ702146A (en) * 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
CN111526874A (zh) * 2017-10-10 2020-08-11 生物基因公司 用于制备螺环衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008240804B2 (en) 2007-04-20 2013-02-21 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
CA2689560A1 (en) * 2007-06-07 2008-12-11 F.Hoffmann-La Roche Ag Prolinamide derivatives as nk3 antagonists
WO2009024502A1 (en) * 2007-08-22 2009-02-26 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as nk3 receptor antagonists
KR20110063862A (ko) 2008-10-09 2011-06-14 에프. 호프만-라 로슈 아게 피롤리딘 ｎ-벤질 유도체
US8022099B2 (en) * 2008-11-03 2011-09-20 Hoffmann-La Roche Inc. N-benzyl pyrrolidine derivatives
US8318759B2 (en) 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
US20110144081A1 (en) 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US20110152233A1 (en) 2009-12-18 2011-06-23 Henner Knust Pyrrolidine compounds

Also Published As

Publication number Publication date
KR101522125B1 (ko) 2015-05-20
RU2598604C2 (ru) 2016-09-27
RU2013135176A (ru) 2015-02-20
CN103282357B (zh) 2014-12-17
US8618303B2 (en) 2013-12-31
EP2661432B1 (en) 2014-11-19
HK1187914A1 (en) 2014-04-17
EP2661432A1 (en) 2013-11-13
MX340508B (es) 2016-07-11
ES2526420T3 (es) 2015-01-12
CN103282357A (zh) 2013-09-04
JP5763211B2 (ja) 2015-08-12
US20120178761A1 (en) 2012-07-12
JP2014501767A (ja) 2014-01-23
BR112013017059A2 (pt) 2020-10-27
WO2012093109A1 (en) 2012-07-12
CA2821640A1 (en) 2012-07-12
KR20130120508A (ko) 2013-11-04

Similar Documents

Publication Publication Date Title
MX361020B (es) Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
PH12015502001A1 (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
NZ749437A (en) Processes and intermediates for making a jak inhibitor
MX2014015501A (es) Carboxamidas heterociclicas fungicidas.
CY1116778T1 (el) Παραγωγα πυραζολιου
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
JP2012097115A5 (es)
MX2016008536A (es) Derivados de fluoro-naftilo.
MX2015014353A (es) Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina.
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
PH12016500427A1 (en) Ethynyl derivatives
MX2011008850A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX340508B (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
NZ705144A (en) Ethynyl derivatives as modulators of mglur5 receptor activity
JP2013526610A5 (es)
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
PE20141168A1 (es) Derivados de pirazolidin-3-ona
BR112013000253A2 (pt) derivados de (3-metilpirrolidin-3-il) metil piridinil éter e seu uso como antagonistas do receptor nk-3
MX2012006293A (es) Derivados de pirrolidina como antagonista del receptor nk-3.
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2011007506A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2009006972A (es) Derivados de espiropiperidina como antagonistas de neuroquinina 3.
AR079509A1 (es) Tiazoles biciclicos como moduladores alostericos de receptores mglur5

Legal Events

Date Code Title Description
FG Grant or registration